focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.00
Bid: 61.00
Ask: 63.00
Change: 0.50 (0.81%)
Spread: 2.00 (3.279%)
Open: 61.50
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.10 Announcement

3 Apr 2007 14:28

Torex Retail PLC03 April 2007 Torex Retail PLC 3 April 2007 Torex Retail PLC ("Torex" or "the Group") Disclosure in accordance with Rule 2.10 of the City Code This announcement is being made further to that issued by Torex on 30 March 2007relating to its appointment of Jefferies International Limited to advise it on arange of strategic options including the possible sale of the Group. In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, Torexconfirms that it has the following relevant securities in issue: - 414,825,509 ordinary shares of 1 pence each under the ISIN code GB 0034291632 - 5.5% sterling denominated convertible bonds due 2011 amounting to £65 million, which are convertible into fully paid preference shares in the capital of Torex Retail (Jersey) Limited and are then exchangeable into up to 75,581,395 fully paid ordinary shares of Torex (based on the initial exchange price of £0.86 pence per ordinary share) under the ISIN code XS 0259948254 ENQUIRIES College Hill Tel: 020 7457 2020 Carl Franklin Mark Garraway Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if anyperson is, or becomes, "interested" (directly or indirectly) in 1% or more ofany class of "relevant securities" of Torex, all "dealings" in any "relevantsecurities" of that company (including by means of an option in respect of, or aderivative referenced to, any such "relevant securities") must be publiclydisclosed by no later than 3.30 pm (London time) on the London business dayfollowing the date of the relevant transaction. This requirement will continueuntil the date on which the offer becomes, or is declared, unconditional as toacceptances, lapses or is otherwise withdrawn or on which the "offer period"otherwise ends. If two or more persons act together pursuant to an agreement orunderstanding, whether formal or informal, to acquire an "interest" in "relevantsecurities" of Torex, they will be deemed to be a single person for the purposeof Rule 8.3. Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevantsecurities" of Torex by Torex or by any of their respective "associates", mustbe disclosed by no later than 12.00 noon (London time) on the London businessday following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevantsecurities" "dealings" should be disclosed, and the number of such securities inissue, can be found on the Takeover Panel's website atwww.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economicexposure, whether conditional or absolute, to changes in the price ofsecurities. In particular, a person will be treated as having an "interest" byvirtue of the ownership or control of securities, or by virtue of any option inrespect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Code, which can also be found on thePanel's website. If you are in any doubt as to whether or not you are requiredto disclose a "dealing" under Rule 8, you should consult the Panel. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.